Knight Therapeutics (TSE:GUD) Upgraded by Raymond James to “Moderate Buy” Rating

Raymond James upgraded shares of Knight Therapeutics (TSE:GUD) to a moderate buy rating in a report issued on Friday morning,Zacks.com reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

GUD has been the topic of a number of other research reports. Stifel Canada raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the company from C$5.75 to C$6.75 in a research note on Tuesday, August 13th.

Knight Therapeutics Price Performance

TSE:GUD traded down C$0.03 during mid-day trading on Friday, hitting C$5.19. 103,800 shares of the company’s stock traded hands, compared to its average volume of 69,560. Knight Therapeutics has a 1 year low of C$5.07 and a 1 year high of C$6.23. The company has a market cap of C$525.28 million, a PE ratio of -25.95, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The firm’s 50 day simple moving average is C$5.71 and its 200 day simple moving average is C$5.73.

Insider Buying and Selling

In other Knight Therapeutics news, Senior Officer Amal Khouri sold 5,000 shares of Knight Therapeutics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of C$5.78, for a total transaction of C$28,919.00. Also, insider Sime Armoyan acquired 90,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of C$5.13 per share, with a total value of C$463,672.44. Corporate insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.